Long-Term Urinary Copper Excretion and Exchangeable Copper in Children With Wilson Disease Under Chelation Therapy.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
17
6
2022
medline:
24
9
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
Determining 24-hour urinary copper excretion (UCE) levels is useful for diagnosing Wilson's disease (WD) and for treatment monitoring. Exchangeable copper (ExC) is a novel potential marker, but its long-term changes have never been described in patients under chelation therapy. Our aim was to describe the long-term changes in ExC levels compared to UCE levels in symptomatic WD pediatric patients under chelation therapy. A retrospective, descriptive, and analytical study including all patients under 18 years of age, diagnosed between 2006 and 2020, and treated with chelation therapy was conducted at the National Reference Center for WD in Lyon. Ceruloplasmin levels, serum copper, 24 h-UCE, ExC, and liver enzymes at diagnosis and during follow-up were analyzed. Our study included 36 patients, predominantly with hepatic form of WD (n = 31). The median [interquartile range (IQR)] age at diagnosis was 10.5 (8.4-13.1) years, and the median (IQR) follow-up duration was 6.3 (3.3-8.8) years. At diagnosis, the median (IQR) ExC value was 1.01 (0.60-1.52) µmol/L. There was a significant decrease during the first year of chelation treatment ( P = 0.0008), then a stabilization. The median (IQR) ExC values was 0.38 (0.22-0.63) µmol/L at 12-18 months and 0.43 (0.31-0.54) µmol/L at 5 years of chelation treatment ( P = 0.4057). Similarly, there was a significant decrease in 24-hour UCE ( P < 0.001) during the first year of chelation treatment, then a stabilization. Our study showed a significant decrease in ExC and 24-hour UCE levels during the first year of follow-up; The dynamics of both biomarkers were similar along the follow-up, demonstrating their usefulness in clinical practice for monitoring WD.
Identifiants
pubmed: 35706098
doi: 10.1097/MPG.0000000000003531
pii: 00005176-202210000-00022
doi:
Substances chimiques
Biomarkers
0
Chelating Agents
0
Copper
789U1901C5
Ceruloplasmin
EC 1.16.3.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e75-e80Informations de copyright
Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primer. 2018;4:21.
Couchonnal E, Lion-François L, Guillaud O, et al. Pediatric Wilson’s disease: phenotypic, genetic characterization and outcome of 182 children in France. J Pediatr Gastroenterol Nutr. 2021;73(4):e80-e86.
Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver Disease in Children. 5th ed. Cambridge: Cambridge University Press, 2021.
Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet. 2006;120:151–9.
Alonso EM, Squires RH, Whitington PF. Acute liver failure in children. Suchy FJ, Sokol RJ, Balistreri WF, eds. In: Liver Disease in Children. 3rd ed. Cambridge: Cambridge University Press, 2007:71–96.
Socha P, Janczyk W, Dhawan A, et al. Wilson’s disease in children: a position paper by the hepatology committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:334–44.
European Association for Study of Liver. EASL Clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671–85.
Guillaud O, Brunet A-S, Mallet I, et al. Relative exchangeable copper: a valuable tool for the diagnosis of Wilson disease. Liver Int Off J Int Assoc Study Liver. 2018;38:350–7.
El Balkhi S, Poupon J, Trocello J-M, et al. Determination of ultrafiltrable and exchangeable copper in plasma: stability and reference values in healthy subjects. Anal Bioanal Chem. 2009;394:1477–84.
Heissat S, Harel A, Um K, et al. Evaluation of the accuracy of exchangeable copper and relative exchangeable copper (REC) in a mouse model of Wilson’s disease. J Trace Elem Med Biol Organ Soc Miner Trace Elem GMS. 2018;50:652–7.
Mohr I, Weiss KH. Current anti-copper therapies in management of Wilson disease. Ann Transl Med. 2019;7:S69.
Chanpong A, Dhawan A. Long-term urinary copper excretion on chelation therapy in children with Wilson disease. J Pediatr Gastroenterol Nutr. 2021;72:210–5.
Twomey PJ, Viljoen A, House IM, et al. Limitations of non-ceruloplasmin-bound copper in routine clinical practice. Gut. 2007;56:154.
El Balkhi S, Trocello J-M, Poupon J, et al. Relative exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson’s disease diagnosis. Clin Chim Acta Int J Clin Chem. 2011;412:2254–60.
Trocello J-M, El Balkhi S, Woimant F, et al. Relative exchangeable copper: a promising tool for family screening in Wilson disease. Mov Disord Off J Mov Disord Soc. 2014;29:558–62.
Poujois A, Trocello J-M, Djebrani-Oussedik N, et al. Exchangeable copper: a reflection of the neurological severity in Wilson’s disease. Eur J Neurol. 2017;24:154–60.
Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int Off J Int Assoc Study Liver. 2003;23:139–42.
Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatol Baltim Md. 2010;52:1948–56.
Walshe JM. The pattern of urinary copper excretion and its response to treatment in patients with Wilson’s disease. QJM Int J Med. 2011;104:775–8.
Woimant F, Djebrani-Oussedik N, Poujois A. New tools for Wilson’s disease diagnosis: exchangeable copper fraction. Ann Transl Med. 2019;7:S70.
Poujois A, Djebrani-Oussedik N, Fluchere F, et al. Cuivre échangeable dans la maladie de Wilson: un biomarqueur de la sévérité de l’atteinte neurologique. Rev Neurol (Paris). 2017;173:S142.
Yim J, Kwon SB, Han JS, et al. Total and exchangeable copper assay using inductively coupled plasma mass spectrometry and establishment of a pediatric reference interval. Arch Pathol Lab Med. 2021;145:877–82.
Poujois A, Woimant F. Challenges in the diagnosis of Wilson disease. Ann Transl Med. 2019;7:S67.
Jacquelet E, Poujois A, Pheulpin M-C, et al. Adherence to treatment, a challenge even in treatable metabolic rare diseases: a cross sectional study of Wilson’s disease. J Inherit Metab Dis. 2021;44:1481–8.